MCID: PHY001
MIFTS: 14

Physiological Polycythemia

Categories: Blood diseases

Aliases & Classifications for Physiological Polycythemia

MalaCards integrated aliases for Physiological Polycythemia:

Name: Physiological Polycythemia 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:8431
NCIt 47 C27311
UMLS 69 C0856817

Summaries for Physiological Polycythemia

MalaCards based summary : Physiological Polycythemia An important gene associated with Physiological Polycythemia is IL1B (Interleukin 1 Beta). The drugs Acetazolamide and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and myeloid.

Related Diseases for Physiological Polycythemia

Symptoms & Phenotypes for Physiological Polycythemia

Drugs & Therapeutics for Physiological Polycythemia

Drugs for Physiological Polycythemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4,Phase 1,Phase 2 59-66-5 1986
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3 Racepinephrine Approved Phase 4
4
Zinc Approved Phase 4 7440-66-6 32051 23994
5 Anticonvulsants Phase 4,Phase 1,Phase 2
6 Carbonic Anhydrase Inhibitors Phase 4,Phase 1,Phase 2
7 diuretics Phase 4,Phase 1,Phase 2
8 Natriuretic Agents Phase 4,Phase 1,Phase 2
9 Epinephryl borate Phase 4
10 Hypoglycemic Agents Phase 4,Phase 2,Phase 3
11 insulin Phase 4
12 Insulin, Globin Zinc Phase 4
13
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
14
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1 55-98-1 2478
15
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
16
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
17
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
18
Peginterferon alfa-2b Approved Phase 3,Phase 1,Phase 2 99210-65-8, 215647-85-1
19
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
20
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
22
Ondansetron Approved Phase 3,Phase 1,Phase 2 99614-02-5 4595
23
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
24
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
25
Morphine Approved, Investigational Phase 3 57-27-2 5288826
26
Lenalidomide Approved Phase 3,Phase 2 191732-72-6 216326
27 Pomalidomide Approved Phase 3,Phase 1,Phase 2 19171-19-8
28
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
29
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
30
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
31
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
32 Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
33
Testosterone Approved, Investigational Phase 3 58-22-0 6013
34
Anagrelide Approved Phase 3 68475-42-3 2182
35 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
36 Analgesics Phase 3,Phase 2,Phase 1
37 Anesthetics Phase 3
38 Anesthetics, Dissociative Phase 3
39 Anesthetics, General Phase 3
40 Anesthetics, Intravenous Phase 3
41 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
42 Excitatory Amino Acid Antagonists Phase 3
43 Excitatory Amino Acids Phase 3
44 Neurotransmitter Agents Phase 3,Phase 2
45 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
46 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
47 Dermatologic Agents Phase 3,Phase 2,Phase 1
48 Antirheumatic Agents Phase 3,Phase 2,Phase 1
49 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
50 Immunosuppressive Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 94)

id Name Status NCT ID Phase Drugs
1 Treatment of High Altitude Polycythemia by Acetazolamide Completed NCT00424970 Phase 4 acetazolamide
2 Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia Completed NCT01013402 Phase 4 Human insulin;Human Insulin
3 Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes Withdrawn NCT00160485 Phase 4 Glyburide;Insulin
4 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
5 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
6 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3 Peg-P-IFN-alpha-2b (AOP2014);Hydroxyurea
7 Metformin in Obese Non-diabetic Pregnant Women Completed NCT01273584 Phase 2, Phase 3 Metformin;Placebo
8 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
11 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
12 AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Active, not recruiting NCT02218047 Phase 3 Pegylated-Proline-interferon alpha-2b;Best available therapy (BAT)
13 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Active, not recruiting NCT01243944 Phase 3 ruxolitinib tablets
14 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Active, not recruiting NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
15 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
16 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Active, not recruiting NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo
17 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
18 H-36731: Finasteride in Management of Elevated Red Blood Cells Withdrawn NCT02548117 Phase 3 Finasteride
19 Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera Completed NCT00241241 Phase 2 pegylated interferon-alfa 2a
20 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2 Imetelstat
21 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
22 Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis Completed NCT01732445 Phase 2 ruxolitinib phosphate;danazol
23 CC-4047 in Treating Patients With Myelofibrosis Completed NCT00669578 Phase 1, Phase 2 CC-4047
24 Lenalidomide and Prednisone in Treating Patients With Myelofibrosis Completed NCT00227591 Phase 2 lenalidomide;prednisone
25 Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation Completed NCT02311569 Phase 2 Mirabegron
26 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis Completed NCT00006367 Phase 2 busulfan;cytarabine;idarubicin
27 Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia Completed NCT00445900 Phase 2 cyclophosphamide;prednisone;thalidomide
28 Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru Completed NCT01187108 Phase 1, Phase 2 N-acetylcysteine;Acetazolamide;Placebo pills
29 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Completed NCT00052520 Phase 1, Phase 2
30 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
31 Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders Completed NCT00002792 Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate;tacrolimus
32 Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
33 Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
34 Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00134004 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
35 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
36 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
37 Bone Marrow Transplant in Treating Patients With Hematologic Cancers Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
38 Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Completed NCT00005622 Phase 2 cyclophosphamide
39 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
40 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
41 Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome Completed NCT00475020 Phase 2 Busulfan;Fludarabine;Thymoglobulin (ATG)
42 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
43 Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia Completed NCT00003619 Phase 1, Phase 2 busulfan;cytarabine;etoposide;fludarabine phosphate;isotretinoin;topotecan hydrochloride
44 Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis Completed NCT01814475 Phase 2 A: Fludarabine + Busulphan;B: Fludarabine + Thiotepa
45 Study of Nivolumab in Patients With Myelofibrosis Recruiting NCT02421354 Phase 2 Nivolumab
46 The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV Recruiting NCT03003325 Phase 2 AOP2014;ASA
47 Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg Recruiting NCT02742324 Phase 1, Phase 2 Ruxolotinib;peg-IFN alpha -2a
48 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Recruiting NCT02556931 Phase 2 Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
49 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
50 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil

Search NIH Clinical Center for Physiological Polycythemia

Genetic Tests for Physiological Polycythemia

Anatomical Context for Physiological Polycythemia

MalaCards organs/tissues related to Physiological Polycythemia:

39
Bone Marrow, Bone, Myeloid, T Cells, Kidney, Liver

Publications for Physiological Polycythemia

Variations for Physiological Polycythemia

Expression for Physiological Polycythemia

Search GEO for disease gene expression data for Physiological Polycythemia.

Pathways for Physiological Polycythemia

GO Terms for Physiological Polycythemia

Sources for Physiological Polycythemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....